Many targets and drugs are being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease (NAFLD), but no one really knows which will turn out b
With two monotherapy candidates having reached Phase III in non-alcoholic steatohepatitis (NASH), combination therapy is driving the next wave of business development activity for the liver disease, a
IN VITRO DIAGNOSTICS Mergers & Acquisitions HalioDx Qiagen NV Qiagen Marseille SA Management of Qiagen NV division Qiagen Marseille SA have formed a new company, HalioDx , through a buy-out
With Wall Street estimating that non-alcoholic steatohepatitis (NASH) could become up to a $40 billion worldwide market in the next 15 years, it’s no surprise that an indication lacking great name rec